Martin Shkreli

Tommy the Hamburger is here again, and this is Historical Depravity, where we dig up the polished bones of history, crack them open, and show you the rot they tried to dress up as greatness. They called these people kings, visionaries, captains of industry, patriots, reformers, whatever flattering bullshit helped the blood dry faster. I'm here to show you what they actually were. Martin Shkreli gets remembered through one especially American lie and one especially internet lie. The American lie says he was an unusually rude but otherwise ordinary market actor, a guy who just said the ugly quiet part out loud in a healthcare system already full of price gouging. The internet lie says he was some kind of troll genius antihero, a smirking chaos goblin who embarrassed polite elites and therefore deserves a weird sort of admiration. Both versions stink. The truth is that Shkreli became a bright vulgar receipt for a healthcare order willing to let private actors hold essential medicine hostage, and he chose to become its most punchable face because he enjoyed the power that came with making sick people financially cornered. That is the myth versus reality split. The myth says he was just playing hardball in a system everyone else already exploited. The reality says he took a life saving drug, raised its price with breathtaking speed, bragged through the backlash, and exposed the moral sewer beneath pharmaceutical pricing by showing how little innovation or scientific labor was actually required to extract suffering for profit. He did not discover a cure. He did not build a miraculous platform. He bought control over an old drug and then treated dependence on that drug as a private revenue opportunity. That is the first mechanism to understand: monopoly without creation. Shkreli's notoriety did not come from inventing something costly and then defending the reward for research. It came from acquiring control over something medically necessary and then weaponizing access. That matters because defenders always try to smuggle innovation into the story, as if every pharma fortune reflects scientific heroism. In his case the ugly economics sat in plain sight. He bought leverage, not discovery. He purchased a choke point and then squeezed. Daraprim is the center of the file because it makes the moral shape impossible to miss. This was not some vanity drug, not some elective luxury product, not a cosmetic upgrade for rich hypochondriacs. It was used to treat a dangerous parasitic infection that particularly threatened immunocompromised patients, including people with AIDS and certain cancer patients. Shkreli's company acquired the rights and then raised the price from thirteen dollars and fifty cents a pill to seven hundred fifty dollars. That move became famous because the number was grotesque enough to punch through public indifference. But the deeper obscenity was not just the size of the increase. It was the logic underneath it: these patients need the drug, therefore the company can take more. That logic is not some wild distortion of capitalism. It is one of capitalism's normal temptations, especially in healthcare, where the buyer is often desperate, poorly informed, non optional, and insulated from true market choice by illness itself. Shkreli mattered because he stripped away the moral cosmetics. Many executives hide the same appetite behind sober language about value, reimbursement, lifecycle management, and maximizing shareholder return. He gave it a sneer and a tweet. The ugliness that others laundered through boardroom calm, he performed in public with a smirk. Fuck me sideways, that made him easier to hate and much easier to see clearly. That does not mean he was merely a symbol. He made actual choices. He raised the price. He defended the increase. He used access control and distribution games to make competition and generic workarounds harder. He treated outrage as publicity and publicity as proof of his own cleverness. The point is not that he was uniquely bad in a uniquely innocent system. The point is that he was both an individual bastard and a revealing product of a larger bastard system. He deserves blame for what he did. The system deserves blame for being built in a way that made what he did legal enough, rational enough, and profitable enough to attempt. That is why the "everyone else does it too" defense is not exculpatory. It is damning in two directions at once. Yes, Shkreli was not alone in demonstrating pharmaceutical greed. No, that does not make him less depraved. It makes him a cleaner example of the rot. When defenders say he merely exposed existing incentives, they accidentally admit the real scandal. The fact that a young hedge fund style operator could step into the drug business, grab an old treatment, and immediately understand that the money sat in extortionate pricing tells you a lot about the system's moral design. He also mattered because he enjoyed the cruelty of visibility. Some executives harm quietly and let patients suffer behind billing systems nobody can narrate. Shkreli seemed to get off on the fact that people were furious. That public contempt matters historically because it turned a structural evil into a personality spectacle. The danger there is obvious. Once the story becomes mostly about one annoying little prick with a punchable grin, the country gets to perform outrage at the individual and skip the architecture. He becomes the villain, the hearing room meme, the pharma goblin, and everybody else in the sector keeps pretending their own price logic is somehow more sophisticated, more justified, more tragic, more adult. It often isn't. It's just less openly gleeful. Still, the personal style matters because it clarifies his understanding of power. He did not behave like a man trapped by unfortunate necessity. He behaved like a man delighted by the asymmetry. Patients needed the drug more than he needed their approval. Hospitals needed supply. Doctors needed access. Families needed treatment. He had what they needed and knew it. That is why the moral vocabulary has to stay sharp here. This was not just pricing strategy. It was hostage economics. Take something medically non optional, tighten control, and then dare the desperate to call you monstrous while the law still calls you a businessman. The victims in this file include the obvious patients who faced higher costs, institutional rationing, insurance obstacles, and treatment stress under the new price structure. But they also include the broader public forced to subsidize and normalize a healthcare model where essential drugs can become speculative assets. Every time a company treats medicine as a tollbooth, the damage spreads outward. Hospitals eat costs and pass them on. Public programs absorb strain. Insurers adjust. Families panic. Doctors waste time navigating financial absurdity instead of focusing on care. The patient nearest the price hike feels the knife first, but the whole healthcare ecosystem starts bleeding around the edges. And because American healthcare is already a maze of billing opacity, profit extraction, and insurance distortion, a lot of people initially processed Shkreli as just another grotesque episode in a bad show. That numbness is part of the problem. The cruelty had become plausible. Plenty of Americans heard the story and thought some version of "of course this can happen here." That is a devastating civic fact. In a less rotten order, a move like that would have seemed politically impossible. Here it looked like a sharper version of business as usual. That means the scandal was not only what Shkreli did. It was also what the country had already been trained to tolerate. The later securities fraud conviction adds another layer but should not distract from the core moral file. He did go to prison, but not because the system decided life saving drug extortion was intolerable. He got nailed on other financial misconduct. That matters because it shows the gap between social disgust and legal design. The public hated him for Daraprim. The state punished him for other fraud. The message underneath is ugly: screwing investors or lying in certain financial channels may trip a wire faster than making sick people pay impossible prices for old medicine. That is not justice. That is misalignment. This is where the false legacy gets especially dangerous. Shkreli's defenders and some bored contrarians try to recast him as a clown, a lesson in media hysteria, or a misunderstood provocateur who became symbolic beyond his actual importance. No. His importance is exactly that he became symbolic. He exposed, in a vulgar form, how stripped down the extraction model could be. Buy. Corner. Raise. Gloat. And because he played the villain so loudly, the industry got to expel him from polite company while preserving the broader conditions that made his move possible. He was the bad apple everybody could boo while the orchard stayed profitable. There is also a class lesson in his performance. Shkreli came out of hedge fund and biotech finance culture where cleverness gets rewarded far more than usefulness, where finding arbitrage matters more than building anything decent, and where suffering often appears only as a line item or pricing opportunity. That culture breeds a certain kind of moral deformity: if you can do it and the law permits it and the spreadsheet smiles, then the only real question becomes whether you are bold enough. Healthcare should be the place where that logic gets stopped cold. Instead, in the United States, it often gets a board seat. And because he was so publicly obnoxious, a lot of institutions got to pretend the problem ended with his personality. That is another lie worth smashing. Shkreli was useful to the system even in disgrace because he concentrated public disgust into one grinning target. Lawmakers could denounce him. Executives could distance themselves. Commentators could perform horror. Meanwhile the deeper pricing architecture stayed standing: patent games, exclusivity tricks, rebate distortions, captive markets, investor pressure, and a healthcare structure that keeps patients structurally weak at the point of need. He looked exceptional. The incentives were not. That means his real historical value is diagnostic. He showed how little moral language survives once medicine is treated like any other asset class. If a spreadsheet says the patient must pay because the patient cannot walk away, then the patient becomes leverage instead of a person. That is the core obscenity. Shkreli did not invent that moral collapse, but he embodied it so nakedly that no one could pretend the issue was just bureaucratic complexity. He turned a buried truth into a public sneer. If you want the mechanism in one blunt sentence, here it is: Shkreli used ownership of a necessary medicine the way a landlord uses ownership of heat in winter. That is why he belongs here. Not because he was the only pharma bastard, and not because he alone built the pricing system, but because he showed with unbearable clarity what happens when healthcare gets treated as a private chokepoint rather than a public obligation. The myth says Martin Shkreli was an abrasive but basically ordinary entrepreneur unfairly demonized for following incentives everyone else already followed. The truth says he became a public face of medical extortion and reveled in the role. Strip away the troll persona, the media circus, the contrarian fanboys, and the excuses about market logic, and what remains is a man who looked at sick people, saw leverage, and called it business. That is the depravity on record. The myth is smaller now, the stink is stronger, and the body count is still the body count. See you in the next grave I have to dig up.